Clever Leaves Holdings Inc. (CLVR): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da cannabis medicinal, a Clever Leaves Holdings Inc. (CLVR) surge como uma empresa global pioneira, posicionando -se estrategicamente na interseção da inovação farmacêutica e do cultivo sustentável. Ao alavancar tecnologias de extração de ponta, parcerias internacionais e uma estrutura robusta de conformidade regulatória, a empresa criou um modelo de negócios sofisticado que transcende as abordagens tradicionais do mercado de cannabis, prometendo revolucionar como os produtos de cannabis médicos são desenvolvidos, distribuídos e integrados à assistência médica e Ecossistemas de bem -estar em todo o mundo.

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com cultivadores de cannabis

Clever Leaves estabeleceu parcerias estratégicas na Colômbia e Portugal para o cultivo de cannabis:

Localização	Área de cultivo	Detalhes da parceria
Colômbia	560.000 pés quadrados de cultivo licenciado	Parceria de cultivo certificada por GMP
Portugal	Instalação licenciada de 220.000 pés quadrados	Acordo de cultivo compatível com GMP da UE

Parcerias de produtos farmacêuticos e de bem -estar

Folhas inteligentes colabora com vários fabricantes farmacêuticos:

• Parcerias de desenvolvimento de produtos farmacêuticos
• Acordos de formulação de cannabis medicinal
• Redes internacionais de distribuição de produtos de bem -estar

Acordos de pesquisa e desenvolvimento

Tipo de instituição	Número de parcerias	Foco na pesquisa
Instituições acadêmicas	3 colaborações de pesquisa ativa	Pesquisa de cannabis medicinal e estudos de canabinóides

Acordos de licenciamento

Licenciamento de distribuição de cannabis medicinal

• Aprovações regulatórias da América Latina
• Licenças de distribuição de maconha medicinal européia
• Permissões de exportação internacionais

Cadeia de suprimentos e parceiros de logística

Região de mercado	Parceiros de logística	Capacidade de distribuição
América do Norte	3 provedores de logística especializados	Capacidade de remessa semanal: 500 kg
Mercado europeu	2 parceiros de distribuição internacional	Distribuição mensal: 250 kg

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: Atividades -chave

Cultivo e extração de cannabis em larga escala

As folhas inteligentes opera instalações de cultivo na Colômbia, abrangendo aproximadamente 1.250 acres. A empresa tem uma capacidade de cultivo licenciada de 1,4 milhão de pés quadrados para a produção de cannabis medicinal.

Localização da instalação	Capacidade de cultivo	Potencial de produção anual
Colômbia	1,4 milhão de pés quadrados	Aproximadamente 250.000 kg de biomassa

Desenvolvimento de produtos de cannabis medicinal

A empresa se concentra no desenvolvimento de produtos de cannabis medicinal farmacêuticos que visam áreas terapêuticas específicas.

• Desenvolvimento de produtos direcionando o gerenciamento da dor crônica
• Extração de canabinóides de grau farmacêutico
• Processos de fabricação certificados por GMP

Conformidade regulatória e garantia de qualidade

As folhas inteligentes mantêm a estrita conformidade regulatória em mercados internacionais.

Certificações regulatórias	Mercados geográficos
Certificação UE-GMP	União Europeia
FDA colombiana equivalente	Colômbia

Expansão do mercado internacional

Folhas inteligentes têm presença operacional em vários países, incluindo Colômbia, Portugal e Estados Unidos.

• Mercados de exportação ativa: Alemanha, Reino Unido
• Redes de distribuição internacional
• Parcerias estratégicas na América do Norte e Europa

Pesquisa e inovação em terapêuticas baseadas em canabinóides

A empresa investe em pesquisa avançada de pesquisa canabinóide e inovação de produtos.

Áreas de foco de pesquisa	Alocação de investimento
Formulações farmacêuticas canabinóides	Aproximadamente US $ 2,5 milhões anualmente
Desenvolvimento de ensaios clínicos	Estimado US $ 1,8 milhão de orçamento de P&D

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: Recursos -chave

Instalações de cultivo licenciadas

Folhas inteligentes opera instalações de cultivo de cannabis licenciadas em:

Localização	Tamanho da instalação	Capacidade de cultivo
Colômbia	200.000 pés quadrados	Aproximadamente 4,4 milhões de gramas por ano
Portugal	74.000 pés quadrados	Aproximadamente 2,2 milhões de gramas por ano

Tecnologias avançadas de extração e processamento

Capacidades tecnológicas:

• Tecnologia de extração supercrítica de CO2
• Processos de destilação e purificação proprietários
• Instalações de fabricação certificadas por GMP

Especialização da equipe de gerenciamento

Liderança -chave	Experiência global de cannabis
CEO Kyle Detwiler	Mais de 12 anos na indústria de cannabis
CFO Louis Battistini	Mais de 15 anos de liderança financeira

Propriedade intelectual

Portfólio de patentes:

• 6 Patentes de cultivo internacional de cannabis registradas
• 3 Patentes de Método de Extração Proprietária
• Investimento de P&D em andamento de US $ 1,2 milhão anualmente

Recursos de conformidade regulatória

Credenciais de conformidade:

• Certificação UE-GMP
• Licenças de cannabis medicinal colombiana e portuguesa
• Equipe abrangente de conformidade regulatória de 12 profissionais

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: proposições de valor

Produtos de cannabis medicinal padronizados de alta qualidade

Folhas inteligentes produz produtos de cannabis de nível médico com um processo de padronização que garante qualidade consistente. A partir do quarto trimestre 2023, a empresa mantém um padrão de qualidade do produto de 99,5% de pureza de grau farmacêutico.

Categoria de produto	Nível de pureza	Volume de produção (kg/ano)
Extratos de cannabis medicinal	99.5%	3,200
Produtos de bem -estar da CBD	99.2%	2,800

Cadeia de suprimentos global com práticas de cultivo sustentável

As folhas inteligentes opera instalações de cultivo em vários locais internacionais com práticas sustentáveis.

• Colômbia: instalação de cultivo de 150 hectares
• Portugal: Site de Cultivo Certificado por UE-GMP de 30 hectares
• Alvo de neutralidade de carbono: 2025
• Taxa de reciclagem de água: 68%

Extratos de canabinóides de grau farmacêutico

A empresa produz extratos canabinóides de grau farmacêutico com composição molecular precisa.

Tipo de extrato	Concentração	Capacidade de produção anual
THC Extratos	99,3% puro	1.500 kg
Isolados de CBD	99,7% puro	2.200 kg

Portfólio de produtos diversificados

As folhas inteligentes mantêm uma gama de produtos abrangente direcionada aos mercados médicos e de bem -estar.

• Óleos de cannabis medicinal
• Suplementos de bem -estar da CBD
• Derivados farmacêuticos de cannabis
• Compostos canabinóides de grau de pesquisa

Conformidade com os padrões regulatórios internacionais

A conformidade regulatória em várias jurisdições garante a acessibilidade do mercado global.

Certificação regulatória	Jurisdição	Status de conformidade
EU-GMP	União Europeia	Certificado
Anvisa	Brasil	Aprovado
Diretrizes da FDA	Estados Unidos	Em andamento

Clever Leaves Holdings Inc. (CLVR) - Modelo de Negócios: Relacionamentos do Cliente

Vendas diretas para empresas farmacêuticas

A partir do quarto trimestre 2023, as folhas inteligentes relataram 17 parcerias ativas em empresas farmacêuticas na América do Norte e na Europa. O volume de vendas para clientes farmacêuticos atingiu US $ 3,2 milhões no último trimestre financeiro relatado.

Região	Número de clientes farmacêuticos	Volume de vendas ($)
América do Norte	9	1,850,000
Europa	8	1,350,000

Suporte e engajamento online do cliente

Folhas inteligentes mantém uma infraestrutura de suporte ao cliente digital com Recursos de resposta 24/7. O tempo médio de resposta é de 2,3 horas nos canais digitais.

• Canais de suporte: email, portal da web, linha de atendimento ao cliente dedicada
• Plataformas de engajamento digital: LinkedIn, site corporativo
• Volume mensal de interação digital: aproximadamente 450 interações com os clientes

Programas de educação profissional médica

Em 2023, folhas inteligentes realizaram 22 sessões de treinamento profissional médico, atingindo 387 profissionais de saúde em várias especialidades.

Tipo de programa	Número de sessões	Os profissionais alcançaram
Webinars	12	215
Workshops pessoais	10	172

Colaboração de pesquisa científica

As folhas inteligentes investiram US $ 1,7 milhão em iniciativas de pesquisa colaborativa durante 2023, em parceria com 6 instituições acadêmicas e de pesquisa.

• Áreas de foco de pesquisa: aplicações de cannabis medicinal, tecnologias de extração de canabinóides
• Parcerias de pesquisa ativa: Universidade de Toronto, Universidade de São Paulo

Serviços personalizados de consulta de produtos

Os serviços de consulta especializados geraram US $ 450.000 em receita durante o último período financeiro relatado, com 127 consultas únicas do cliente.

Tipo de consulta	Número de consultas	Receita ($)
Consultas profissionais médicos	82	275,000
Consultas institucionais de clientes	45	175,000

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: canais

Equipe de vendas diretas

A partir do quarto trimestre de 2023, as folhas inteligentes mantêm uma equipe de vendas direta focada em maconha medicinal e mercados farmacêuticos na América do Norte e na América Latina.

Região	Tamanho da equipe de vendas	Mercado -alvo
América do Norte	12 representantes	Dispensários de cannabis medicinal
América latina	8 representantes	Distribuidores farmacêuticos

Plataformas online de comércio eletrônico

As folhas inteligentes utilizam plataformas digitais para vendas B2B e B2C em mercados regulamentados.

• Plataforma primária de comércio eletrônico: cleverleavesrx.com
• Transações online mensais médias: 247
• Receita de vendas digitais: US $ 1,2 milhão em 2023

Conferência Médica e Participação da Feira

Em 2023, as folhas inteligentes participaram de eventos importantes da indústria:

Conferência	Localização	Data	Novos contatos gerados
MJBIZCON	Las Vegas, nv	Novembro de 2023	86 leads potenciais de negócios
Cannmed Conference	Boston, MA	Setembro de 2023	53 leads potenciais de negócios

Redes de distribuidores farmacêuticos

Folhas inteligentes mantém parcerias estratégicas com distribuidores farmacêuticos:

• Total de parcerias de distribuidores: 7 redes ativas
• Cobertura geográfica: Colômbia, Brasil, Estados Unidos
• Receita do canal de distribuição: US $ 4,3 milhões em 2023

Plataformas de marketing e informação digitais

A estratégia de marketing digital se concentra em divulgação direcionada:

Plataforma	Seguidores/assinantes	Taxa de engajamento
LinkedIn	12.500 seguidores	3.2%
Twitter	8.700 seguidores	2.7%
Site da empresa	47.000 visitantes mensais	4.1%

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: segmentos de clientes

Pesquisadores de cannabis medicinal

Folhas inteligentes serve pesquisadores de cannabis medicinal através dos seguintes segmentos:

Categoria de pesquisa	Volume anual estimado	Alcance geográfico
Instituições de Pesquisa Clínica	37 Parcerias de Pesquisa Ativa	América do Norte, América Latina, Europa
Programas de pesquisa acadêmica	12 colaborações universitárias	Redes de pesquisa internacionais

Empresas farmacêuticas

O envolvimento do cliente farmacêutico inclui:

• Parcerias de desenvolvimento farmacêutico ativo: 8
• Valor do contrato farmacêutico total: US $ 14,2 milhões
• Instalações de produção certificadas GMP: 2

Profissionais de saúde

Segmento profissional	Mercado -alvo	Nível de engajamento
Médicos	420 médicos registrados	Alto apoio educacional
Especialistas	167 profissionais médicos especializados	Programas de educação médica em andamento

Bem -estar e mercados nutracêuticos

Detalhes de penetração no mercado:

• Linhas de produtos nutracêuticos: 6
• Mercados internacionais de bem -estar: 5 países
• Receita anual de produtos de bem -estar: US $ 3,7 milhões

Pacientes internacionais de cannabis medicinal

Região	Acesso ao paciente	Conformidade regulatória
América latina	22.000 pacientes registrados	Colômbia, aprovações regulatórias do Brasil
América do Norte	15.400 pacientes registrados	Canadense, conformidade no nível estadual dos EUA
Mercados europeus	8.600 pacientes registrados	Estruturas regulatórias alemãs do Reino Unido

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: estrutura de custos

Cultivo de cannabis e despesas de produção

A partir de 2023 Q3 Relatório financeiro, as folhas inteligentes relataram despesas totais de cultivo e produção de US $ 3,7 milhões. Repartição dos principais custos de produção:

Categoria de despesa	Custo anual ($)
Custos operacionais de estufa	1,250,000
Despesas de mão -de -obra	1,100,000
Aquisição de matéria -prima	850,000

Investimentos de pesquisa e desenvolvimento

As despesas de P&D para 2023 totalizaram US $ 1,2 milhão, focadas em:

• Desenvolvimento de deformação genética
• Melhorias da tecnologia de extração
• Pesquisa de formulação de produtos

Custos regulatórios de conformidade e licenciamento

Despesas regulatórias anuais documentadas em US $ 750.000, incluindo:

Área de conformidade	Custo anual ($)
Licenciamento internacional	350,000
Certificação de qualidade	250,000
Consultoria jurídica	150,000

Expansão do mercado internacional

Custos de expansão geográfica: US $ 2,1 milhões em 2023, alocados de forma alta:

• Entrada no mercado latino -americano
• Aprovações regulatórias européias
• Desenvolvimento de infraestrutura de distribuição

Manutenção de tecnologia e infraestrutura

Investimento de tecnologia para 2023: US $ 980.000, incluindo:

Categoria de tecnologia	Custo anual ($)
Infraestrutura de TI	450,000
Licenciamento de software	270,000
Segurança cibernética	260,000

Clever Leaves Holdings Inc. (CLVR) - Modelo de negócios: fluxos de receita

Vendas de produtos de cannabis medicinal

Q3 2023 Receita total: US $ 2,4 milhões

Categoria de produto	Receita ($)	Quota de mercado
Flor de cannabis seca	1,050,000	43.75%
Extratos de cannabis	780,000	32.5%
Óleos de cannabis medicinal	570,000	23.75%

Licenciamento de ingredientes farmacêuticos

Receita de licenciamento para 2023: US $ 1,2 milhão

• Acordos ativos de licenciamento de ingredientes farmacêuticos: 3
• Valor médio do contrato de licenciamento: US $ 400.000
• Cobertura geográfica: Colômbia, Alemanha, Canadá

Contratos de pesquisa e desenvolvimento

Receita de contrato de P&D em 2023: $ 850.000

Tipo de contrato	Número de contratos	Valor total ($)
Pesquisa acadêmica	2	350,000
Desenvolvimento farmacêutico	1	500,000

Distribuição do mercado internacional

Receita de distribuição internacional: US $ 1,8 milhão em 2023

• Mercados internacionais ativos: 5
• Regiões de exportação primárias: América Latina, Europa
• Volume de exportação: 250 kg de produtos de cannabis medicinal

Serviços de extração e processamento

Receita dos Serviços de Extração: US $ 680.000 em 2023

Tipo de serviço	Receita ($)	Contagem de clientes
Extração de terceiros	480,000	12
Processamento personalizado	200,000	5

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Value Propositions

You're looking at the core value Clever Leaves Holdings Inc. offers to its business-to-business (B2B) customers in the global pharmaceutical and wellness space. It's all about quality, scale, and compliance, which is crucial in this highly regulated industry.

Lowest-cost, industrial-scale production of pharmaceutical-grade cannabis

Clever Leaves Holdings Inc. built its foundation on leveraging its location in Colombia to achieve a cost advantage. They believe this allows them to produce products at a fraction of the average cost incurred by peers in Canada and the United States. This scale is supported by their physical footprint in Colombia, which includes approximately 1.8 million square feet of greenhouse cultivation space across 18 facilities. Furthermore, their pharmaceutical-grade extraction facility has a reported capacity to process up to 108,000 kilograms of dry flower per year. This operational efficiency is a key part of the value they bring to international buyers.

Guaranteed compliance with stringent EU-GMP quality standards

For pharmaceutical markets, certification is everything. Clever Leaves Holdings Inc. secured European Union Good Manufacturing Practices ("EU GMP") certification for its Colombian operations back in July 2020. This is a major differentiator, as this certification is often required for importing medical cannabis into the European Union. They also hold Australian GMP certifications from the Therapeutic Goods Administration ("TGA"), which they received in December 2023. This commitment to quality standards provides customers with confidence in the product's suitability for intended use.

The scope of their certifications is broad, covering:

• API (Active Pharmaceutical Ingredients)
• Semi-finished cannabis products
• Finished cannabis products

Reliable, diversified global supply chain to over 15 countries

The value proposition includes the ability to reliably move product across borders. Clever Leaves Holdings Inc. has established a global footprint, successfully exporting to more than 15 countries. This network includes key regulated markets. The company's 2021 production quota from the Colombian government was substantial, authorizing them to manufacture up to approximately 59,000 kilograms of cannabis into dried flower derivatives, which at the time represented about 18% of the world's legal medical cannabis production quota for that year.

Here's a look at some of the markets they serve:

Region/Country	Product Focus
Germany	Medical Cannabis Imports
Australia	TGA Certified Products
Brazil	Cannabinoid Distribution
United Kingdom	Pharmaceutical Channel Supply
Czech Republic	Medical Cannabis Extracts

High-quality Active Pharmaceutical Ingredients (APIs) and finished flower

Clever Leaves Holdings Inc. focuses on producing both the raw, high-purity components and the final consumer-ready product. They produce cannabinoid active pharmaceutical ingredients (API) and finished products in both flower and extract form for their B2B clientele. This dual output capability allows them to serve different parts of the value chain, from pharmaceutical formulators needing isolates to distributors requiring dried flower.

Dual-segment offering (Cannabinoid and Non-Cannabinoid, pre-sale)

You aren't just buying cannabis; you are engaging with a company that has two distinct revenue drivers. The business operates through the Cannabinoid segment, which handles cultivation, extraction, and distribution of cannabis products internationally. The other stream is the Non-Cannabinoid segment, which formulates and sells nutraceuticals and other natural remedies, wellness products, and dietary supplements, primarily to retailers in the United States. To be fair, the Non-Cannabinoid segment historically generates the maximum revenue for the company. For instance, the trailing twelve-month revenue reported for 2023 was $17.42 million, with the latest reported annual revenue for 2024 reaching $17.7 million.

The segments break down like this:

• Cannabinoid: Cultivation, extraction, APIs, flower.
• Non-Cannabinoid: Nutraceuticals, wellness products, supplements.

The company's financial performance shows the challenge: 2023 saw revenue of $17.42 million against losses of -$17.90 million.

Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Relationships

You're looking at how Clever Leaves Holdings Inc. manages its relationships with the entities buying its pharmaceutical-grade cannabis products, especially now that they've gone private. The strategy clearly pivots around high-touch service for regulated B2B buyers and cost-conscious execution for bulk sales.

Dedicated B2B account management for pharmaceutical clients

For pharmaceutical clients, the relationship is managed through dedicated B2B account management. This is crucial because you're dealing with Active Pharmaceutical Ingredients (APIs) and finished products requiring stringent quality control. Clever Leaves Holdings Inc. focuses its commercial efforts on key international markets, including Australia, Brazil, Germany, Israel, and the United Kingdom, as part of its post-delisting strategy. The company's operations in Colombia produce EU GMP cannabinoid APIs and finished products for this growing base of B2B customers globally. As of the end of 2023, cannabinoid sales, which feed these B2B relationships, had surged by 39% year-over-year, reaching $6.6 million of the total $17.4 million revenue for that year. This indicates the high value placed on these specific customer accounts.

Long-term, high-volume supply contracts with fixed terms

The foundation of the pharmaceutical client relationship is built on securing long-term, high-volume supply contracts. These agreements lock in demand for the company's output, providing revenue visibility. The process for securing these involves a multi-step validation: identifying a prospective customer, defining product specifications, securing country-specific regulatory approval, and finally, achieving repeat/regular purchase orders after an initial validation shipment. While specific 2025 contract values aren't public, the 2023 revenue of $17.42 million reflects the scale of these ongoing commitments.

Regulatory and technical consulting support for partners

Clever Leaves Holdings Inc. supports its partners by leveraging its regulatory expertise, which is a key value-add in this complex sector. The company holds multiple international certifications, including European Union Good Manufacturing Practices (EU GMP) Certification, a GMP Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. This deep compliance knowledge helps partners navigate import/export permits and product acceptance. The company's Chief Regulatory Officer is a key part of this relationship structure.

Direct, transactional sales for bulk dried flower exports

For bulk dried flower, the relationship model shifts to be more direct and transactional, focusing on leveraging low-cost production. The company aims to commercially launch high-THC flower produced in Colombia. Historically, Clever Leaves Holdings Inc. has executed significant flower transactions; for example, they exported 30 kg of high-THC cannabis flower from Portugal to a U.S. partner in October 2021. Furthermore, a past research initiative involved pledging up to 5 tons of cannabis flower at no cost to advance U.S. scientific research, showing a willingness to transact large volumes based on strategic need.

The following table summarizes the different customer engagement types and associated scale indicators:

Customer Relationship Type	Primary Product Focus	Key Metric/Scale Indicator	Geographic Focus (Post-2024 Strategy)
Dedicated B2B Account Management	APIs, Finished Pharmaceutical Products	Cannabinoid Revenue: $6.6 million (2023)	Germany, Brazil, Australia, Israel, UK
Long-Term Supply Contracts	EU GMP Certified Materials	Total Revenue: $17.4 million (2023)	Global B2B Network
Regulatory/Technical Support	All Products	Holding EU GMP, GACP Certifications	Partners requiring compliance pathways
Direct/Transactional Sales	Bulk Dried Flower	Historical Flower Export: 30 kg (Single Shipment)	Markets with high flower demand

Investor relations and public disclosure (voluntary delisting in 2024)

The relationship with public market investors fundamentally changed in 2024. Clever Leaves Holdings Inc. voluntarily delisted from NASDAQ around May 16, 2024, and subsequently filed a Form 15 to suspend reporting obligations under the Exchange Act, meaning no more mandatory Forms 10-K, 10-Q, and 8-K. This was done to reduce the significant operating expense and regulatory burden associated with public trading. The company's market capitalization as of December 4, 2025, stood at $526.00, a significant decrease from its prior public standing, reflecting the shift away from public market scrutiny. The company now communicates material information through its website and press releases, a different relationship dynamic than required by the SEC.

• Investor communication channels now include the company website (https://cleverleaves.com) and social media.
• The decision to delist was partly due to non-compliance with Nasdaq's listing requirements.
• The company aims to continue reducing operating expenses, having achieved a 26% reduction in General and Administrative expenses in Q4 2023.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Channels

You're looking at how Clever Leaves Holdings Inc. gets its pharmaceutical-grade cannabinoid products out to the world, which is critical given their focus on international, regulated markets. The channel strategy heavily relies on certified partners and direct export from their primary production hub.

Direct B2B sales force targeting pharmaceutical and CPG companies

The core of the B2B approach involves direct engagement with pharmaceutical entities for Active Pharmaceutical Ingredients (APIs) and finished products. For instance, the company has a five-year agreement to supply EU-GMP-certified CBD extracts from Colombia to SOMAÍ Pharmaceuticals in Portugal. This direct supply channel is designed to feed European drug delivery systems. While specific 2025 revenue attribution to the direct sales force isn't public, the company's total trailing 12-month revenue as of December 31, 2023, stood at $17.42M.

International distribution partners and licensed importers

Clever Leaves Holdings Inc. uses established local entities to navigate complex regulatory landscapes. In Germany, Cansativa, a Frankfurt-based certified importer and distributor, handles sales and distribution of Clever Leaves' extracts and oral solutions. The company's investment in Cansativa accelerated its participation in that specific market. Historically, Clever Leaves has exported to over 15 countries, demonstrating a broad network of potential or existing distribution relationships.

The structure of these partnerships can be summarized:

Market/Partner Type	Known Partner Example (as of latest data)	Product Supplied	Facility Origin
European Biopharma	SOMAÍ Pharmaceuticals	EU-GMP-certified CBD extracts	Colombia
German Distributor	Cansativa	Extracts and oral solutions	Colombia
Australian Partner	Cannatrek	White label finished products (OS 20%CBD and OS 10%CBD)	Colombia (Historical context)

Direct export from Colombia and Portugal facilities

The primary export channel centers on the Colombian greenhouses, which span over 1.8 million square feet of fully built-out cultivation capacity. The extraction facility there was capable of extracting 104,400 kilograms of dried flower annually, with expansion underway to reach 324,000 kilograms per year. It is important to note that cultivation and manufacturing activities in Portugal ceased in full by the end of the first quarter of 2023, meaning all 2025 dry flower exports are solely from the Colombian facility. The company has secured significant production quotas, representing 50% of Colombia's total quota and approximately 18% of the world's legal medical cannabis production quota for 2021, setting the stage for export capacity.

Academic and research institution supply channels

This channel focuses on supplying material to advance scientific knowledge. In a notable 2021 initiative, Project Change Lives, Clever Leaves Holdings Inc. pledged up to USD $25,000,000 retail value of medical cannabis products to eligible U.S. organizations. This included offering up to 250,000 bottles of cannabis oil or approximately 5 tons of medical cannabis flower, provided at no cost to research partners.

Key research supply metrics:

• Pledged product value: Up to $25,000,000 (retail value).
• Product volume offered: Up to 250,000 bottles of oil.
• Product volume offered: Up to 5 tons of flower.
• Compliance standard: Pharmaceutical-grade cannabis.

Digital presence for corporate and investor communication

The digital channel supports corporate visibility and investor relations, though specific 2025 engagement metrics are not available. The company maintains its listing on the Nasdaq under ticker symbol CLVR (though trading has seen extreme volatility, with a market cap reported at $526.00 as of December 4, 2025). The digital presence is used to communicate operational milestones, such as receiving EU-GMP certification for its Colombian facilities, which is generally required to import into the European Union. The company also reports having nearly 300 full-time employees as of late 2024/early 2025 data points.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Segments

You're looking at the core buyers for Clever Leaves Holdings Inc. as of late 2025. The business model is heavily weighted toward B2B supply in the pharmaceutical and medical cannabis space, leveraging its Colombian cultivation and EU GMP certifications. Honestly, the biggest shift impacting this section recently was the divestiture of the other side of the business.

The company operates primarily through its Cannabinoid segment, which focuses on cultivation, extraction, and distribution of pharmaceutical-grade products. For context, the full-year 2024 revenue reached $17.7 million, building on the 2023 full-year cannabinoid revenue growth of 39%.

The customer base is segmented by the type of regulated product required:

• Global Pharmaceutical and Biotech Companies requiring Active Pharmaceutical Ingredients (API) and standardized extracts.
• International Medical Cannabis Distributors and Importers needing registered flower and extract products.
• Academic and Government Research Institutions requiring validated, traceable cannabis material.
• Nutraceutical and Wellness Brands, though this group is now largely historical following a major transaction.

The Non-Cannabinoid segment, which served mass and specialty retailers in the U.S. with wellness products and nutraceuticals, was sold off. Clever Leaves Holdings Inc. completed the sale of this herbal brands business on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing. So, that customer group is no longer a focus for the current structure.

The international reach is significant, with export shipments having reached over a dozen jurisdictions, including Germany, Brazil, the United Kingdom, and Australia. The focus remains on providing lower-cost, reliable supply to these partners.

Here's a breakdown of the primary B2B customer types within the core Cannabinoid segment:

Customer Segment Focus	Product Form Supplied	Geographic Sales Focus (Primary)	Key Requirement Met
Global Pharmaceutical and Biotech Companies	Active Pharmaceutical Ingredients (API), Oral Solutions, Standardized Extracts	Primarily outside of the U.S.	EU GMP Certification and Traceability
International Medical Cannabis Distributors and Importers	Cannabis Flowers (THC/CBD), Full Spectrum Extracts	Germany, Brazil, Australia, and others (over 15 countries served historically)	Reliable, Year-Round Supply and Product Registrations
Academic and Government Research Institutions	Validated Extracts, Specific Cultivar Material	Global (subject to local regulation)	Consistent Quality and Cultivar Registration (e.g., through Paradise Seeds collaboration)
CPG Companies (B2B Ingredient Supply)	Cannabidiol (CBD) Isolates	International Markets	Bulk Ingredient Supply for Downstream Formulation

The company's production locations in Colombia, which boast over 10 million square feet of licensed cultivation capacity, are key to serving these segments with environmentally sustainable, industrial-scale output. This capacity supports the consistent supply needed by major international importers and pharmaceutical partners.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Cost Structure

You're looking at the cost side of Clever Leaves Holdings Inc. (CLVR)'s operations, which is heavily influenced by its strategic pivot to low-cost, high-quality production centered in Colombia. The structure clearly shows a trade-off between high initial compliance costs and low ongoing cultivation expenses.

High fixed costs for maintaining GMP-certified facilities and compliance are a given when you operate at a pharmaceutical standard. Clever Leaves Holdings Inc. maintains its EU GMP-certified extraction operation and cultivation facilities in Colombia, which span over 1.8 Million sq. ft. of fully built-out capacity. These certifications are not cheap to acquire or maintain, representing a significant fixed overhead necessary to access premium international markets like Germany and Australia.

The core advantage, however, lies in the low variable cultivation costs due to Colombian climate advantage. The equatorial location provides a consistent 12 hours of sunlight year-round, reducing the need for costly light supplementation and minimizing pesticide use. This natural advantage allowed Clever Leaves Holdings Inc. to produce cannabis at a reported cost as low as $0.20 per gram in high volume, which was roughly 1/10 the cost of many leading Canadian producers at the time of that comparison. To be fair, the all-in cost per gram of dry flower was reported at $0.75 in FY 2023, up from $0.36 in FY 2022, a change management attributed to reduced agricultural output early in 2023 and quality improvements.

The company has been aggressively tackling overhead through significant operating expense reduction. Reflecting these optimization efforts, Clever Leaves Holdings Inc. drove year-over-year General and Administrative (G&A) expense reductions of 24% for the full year 2023. For the fourth quarter of 2023 specifically, the G&A cut was 26% year-over-year. Total Operating Expenses improved significantly, moving from $54.14 Million in FY 2022 down to $22.15 Million in Q4 2023. This focus on capital efficiency was further supported by divestitures, such as the sale of Portuguese farm assets for $1.5 Million and the sale of the Non-Cannabinoid Herbal Brands Business for $8.02 Million.

When we look at the Costs of Goods Sold (COGS) and Gross Margin, the picture is clearer when using the adjusted figures, which strip out one-time inventory provisions. The outline mentioned a 45% gross margin target for FY 2024; the company achieved an Adjusted Gross Margin of 45.4% in FY 2023. The latest reported margin figure available, as of late 2025 context, is 37.64%. Here's a look at the core COGS components from the last full financial report (FY 2023):

Metric (USD Millions)	FY 2023	FY 2022
Total Revenue	$17.42	$16.41
Cost of Revenue (COGS)	$10.86	$9.19
Gross Profit (Reported)	$6.56	$7.22
Adjusted Gross Margin	45.4%	56.3%

Finally, International regulatory and legal compliance expenses are embedded within both fixed costs and operating expenses. Clever Leaves Holdings Inc. is structured to supply pharmaceutical-grade products to over 15 countries globally, including key markets like Australia, Brazil, and Germany. Successfully navigating the distinct import and quality regulations in each jurisdiction requires dedicated legal and regulatory teams, which contributes to the sustained Selling, General & Admin (SG&A) spend, which totaled $20.03 Million in FY 2023.

You should review the cash flow statement to see how the divestiture proceeds of $8.02 Million from the Herbal Brands sale are being allocated against ongoing compliance and operational burn rate. Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Revenue Streams

You're looking at how Clever Leaves Holdings Inc. actually brings in the money now that the focus is purely on high-quality, EU-GMP certified cannabis for global pharmaceutical markets. The numbers tell a clear story of strategic divestiture and focus on the core cannabinoid business.

The Total annual revenue for the fiscal year 2024 was reported to be approximately $17.7 million.

The shift away from the diversified model is concrete, marked by the divestiture of the non-core business:

• Sales from the Non-Cannabinoid segment (prior to March 2024 sale): The sale of the Herbal Brands business was completed on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing.

The remaining, core revenue streams are entirely within the cannabinoid segment, which includes both API/extracts and dried flower exports. While the precise 2024 breakdown isn't public, the 2023 figures show the relative weight before the sale:

Revenue Stream Type (Based on 2023 Data)	Reported Annual Revenue (FY 2023)
Cannabinoid Revenue (API, Extracts, Flower)	$6.6 million
Non-Cannabinoid Revenue (Sold in 2024)	$10.9 million
Total Annual Revenue (FY 2023)	$17.4 million

The primary focus of the current revenue generation is:

• Sales of Cannabinoid Active Pharmaceutical Ingredients (API) and extracts: These are produced in Colombia under EU-GMP standards and sold to B2B customers globally.
• Revenue from bulk EU-GMP certified dried cannabis flower exports: Shipments are supported by certifications including EU GMP, Australian GMP, and ANVISA GMP, targeting markets like Australia, Germany, and Israel.

The entire structure of the cannabinoid business is built around securing long-term commercial relationships, which is the mechanism for future revenue stability. The commercial strategy involves a multi-step process to convert initial shipments into recurring sales:

• Revenue from long-term B2B supply agreements: The business model is focused on partnering with leading and emerging cannabis and pharmaceutical businesses by providing them with lower cost product and reliable supply.
• The pathway to securing this revenue involves: Identify Prospective Customer, Develop & Country-Specific Regulatory Path Determined, Quality Systems Audit, New Supply Agreement Secured, Initial Pathfinder Shipment, Validation of Product Quality, Country-Specific Regulatory Approval, Apply for & Obtain Export & Import Permits, 1st Commercial Shipment, Receive Market Feedback, Achieve Acceptance, and finally, Expect to Achieve Repeat/Regular Purchase Orders.

Finance: draft 13-week cash view by Friday.